LYEL
Lyell Immunopharma, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Lyell Immunopharma, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Lyell Immunopharma, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Lyell Immunopharma, Inc..
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Lyell Immunopharma, Inc.
15.21
+4.44 · +41.19%
post 15.74 +3.51%
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Manager | Value | % base | |
|---|---|---|---|
| Arch Venture | $45.5M | 26.89% | 0.00% |
| Glaxosmithkline | $21.3M | 12.55% | 0.00% |
| Vanguardindex-like | $11.1M | 6.53% | +9.55% |
| Orland Properties | $10.6M | 6.26% | 0.00% |
| BlackRockindex-like | $10.2M | 6.01% | +277.62% |
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Arch Venture | $45.5M | 26.89% | 0.00% |
| Glaxosmithkline | $21.3M | 12.55% | 0.00% |
| Vanguardindex-like | $11.1M | 6.53% | +9.55% |
| Orland Properties | $10.6M | 6.26% | 0.00% |
| BlackRockindex-like | $10.2M | 6.01% | +277.62% |
—
—
Expected move
No implied move.